| Literature DB >> 20700431 |
Vanitha Sivanaser1, Pirjo Manninen.
Abstract
The preoperative assessment of the patient for neurosurgical and endovascular procedures involves the understanding of the neurological disease and its systemic presentation, and the requirements of the procedure. There is a wide spectrum of different neurosurgical disorders and procedures. This article provides an overview of the preoperative evaluation of these patients with respect to general principles of neuroanesthesia, and considerations for specific intracranial and vascular neurosurgical and interventional neuroradiological procedures.Entities:
Year: 2010 PMID: 20700431 PMCID: PMC2911602 DOI: 10.1155/2010/241307
Source DB: PubMed Journal: Anesthesiol Res Pract ISSN: 1687-6962
Glasgow Coma Scale.
| Parameter | Score |
|---|---|
|
| |
| Spontaneously | 4 |
| To speech | 3 |
| To pain | 2 |
| None | 1 |
|
| |
|
| |
| Orientated | 5 |
| Confused | 4 |
| Inappropriate words | 3 |
| Incomprehensible sounds | 2 |
| None | 1 |
|
| |
|
| |
| Obeys commands | 6 |
| Localizing pain | 5 |
| Withdraws from pain | 4 |
| Flexion to pain | 3 |
| Extension to pain | 2 |
| None | 1 |
Patients with a scale score less than 7 require intubation for airway protection.
Pituitary tumors and frequency of occurrence.
| Pituitary tumor | Hormone secreted | Frequency of occurrence |
|---|---|---|
| Prolactinoma | Prolactin | 20–30% |
| Cushing's disease | Adenocorticotropic hormone | 10–15% |
| Acromegaly | Growth Hormone | 5–10% |
| Gonadotroph | Follicle stimulating Hormone/Lutenising hormone | 5% |
| Thyrotropic | Thyroid Stimulating Hormone | <3% |
| Mixed cell adenoma | None | 20–30% |
| Nonfunctioning adenomas | None | 20% |
Differences between diabetes insipidus and syndrome of inappropriate antidiuretic hormone.
| Diabetes insipidus | Syndrome of inappropriate | |
|---|---|---|
| antidiuretic hormone | ||
| Presentation | Polyuria Thirst (awake patients) | Hyponateriamia |
| Serum sodium | Increased >145 mEq/L | Decreased <135 mEq/L |
| Serum osmolarity | High >310 mOsm/L | Low/hypotonic <275 mOsm/L |
| Urine volume | Increased volume >4 L/day | Low |
| Treatment | Supportive fluid replacement and DDAVP | Fluid restriction with hypertonic sodium correction if serum sodium <120 mEq/L |
Systemic effects of Parkinson's disease.
| System | Clinical signs/symptoms | Relevant investigations |
|---|---|---|
| Central nervous system | Muscle rigidity, Tremors, Depression, Hallucination, Akinesia | Neurological assessment Psychological assessment |
| Autonomic nervous system | Difficulty or alteration in salivation, Gastrointestinal function, Temperature regulation, Seborrhoea | Gastrointestinal studies |
| Cardiovascular system | Hypertension, Arrhythmias, Orthostatic hypotension | Electrocardiogram, Echocardiogram |
| Respiratory system | Retained secretions, Atelectasis, Respiratory Infections, Aspiration Pneumonia | Chest radiograph, Arterial blood gases, Spirometry, Pulmonary function test |
| Gastrointestinal system | Dysphagia, Sialorrhoea, Esophageal dysfunction, Weight loss | Serum albumin, electrolytes, creatinine |
| Endocrine system | Altered glucose metabolism | Blood glucose level |
Medical therapy for Parkinson's disease.
| Drugs | Side effects |
|---|---|
| Dopamine agonist | |
| Bromocriptine, Carbegoline, | Nausea/vomiting, |
| Ramipraxole, Ropinirole | Delusions/hallucinations, |
| Hypotension, Dysrhythmias | |
|
| |
| Dopamine precursors | |
| Levodopa, Carbidopa, Sinemet | Similar to Dopamine Agonist |
|
| |
| Anticholinergics | |
| Benzotropine | Confusion/hallucination, |
| Sedation/drowsiness, Dry mouth, | |
| Urinary retention | |
|
| |
| MAOI-B inhibitors | |
| Selegiline | Diarrhea |